Chairman of the Board
Martin Bonde, Ph.D., B.Comm.
- CEO in EpiTherapeutics ApS.
- Serial entrepreneur. Founded and managed several companies in Denmark and USA (NatImmune A/S, Arpida A/S, Combio A/S, CelTor Inc., Torsana Biosensor).
- Fronted several successful exits over the last decade (e.g., NatImmune A/S to IPC; Combio A/S to Arpida AG; and Torsana Biosensor A/S to Celtor Inc). Experience heading out-licensing, acquisitions, in-licensing etc.
BoD
Peter Moldt, Ph.D.
- Partner in Novo Ventures, Novo A/S.
- Member of the board of directors of Cytochroma Inc. Co-founded Curalogic A/S in 2004, served as CEO until 2009 and took the company public in 2006. From 2000-2004, Chief Operating Officer of 7TM Pharma A/S, which he also co-founded. Previously, worked for 11 years with NeuroSearch A/S, with responsibilities for all aspects of pre-clinical and clinical drug development.
- Ph.D. in medicinal chemistry from the Royal Danish School of Pharmacy, and postdoctoral fellow with Yale University`s department of organic chemistry.
BoD
Kim Dueholm, Ph.D.
- Partner in Novo Ventures, Novo A/S, since 2000.
- Member of the board of directors of f-star GmbH.
- Has previously held various positions with Novo Nordisk A/S, e.g., as Patent Portfolio Analyst and Principle Scientific Analyst. Research and venture fund experience in San Francisco, USA, and Osaka, Japan.
- Ph.D. in organic chemistry from the University of Copenhagen and MSc in chemistry/business administration from Odense University.
BoD
Sten Verland, Ph.D.
- Partner and co-founder at Sunstone Capital A/S.
- Serves on the board of directors of Orphazyme ApS, Zymenex A/S (chairman), Action Pharma A/S (chairman), F2G Ltd., Scanbur A/S, StemCare A/S, and Vaximm AG.
- Serial biotech entrepreneur. Has been involved in the start-up and management of several companies including Synarc Inc., M&B A/S (now Taconic Europe), and StemCare A/S. Previously: VP General Manager Europe at Synarc, Inc., CEO and co-owner at M&B A/S. Postdoctoral fellow at University of Copenhagen, and Ph.D. in Immunology, University of Copenhagen.
BoD
Hakan Goker, Ph.D.
- Principal at Aescap Venture.
- Serves on the boards of f-Star, Protaffin and to-BBB.
- Joined Aescap from Atlas Venture where he was instrumental in the formation, management and business strategy of portfolio companies Bicycle Therapeutics, f-Star, Nimbus Discovery, Lumavita, Nitec now Horizon Pharma, and Egalet.
- Previously postdoctoral fellow at the Institute of Cancer Research / Royal Marsden Hospital and the Breakthrough Breast Cancer Centre, UK, in fields of oncology, stem cells and embryonal development.
- Ph.D. in molecular biology and genetics from the University of London.
BoD
Bo Jesper Hansen, M.D., Ph.D.
- Chairman of the board at public company Swedish Orphan Biovitrum.
- Various executive positions in Swedish Orphan International AB since 1993 (CEO in the period 1998-2010).
- Board member of Gambro AB, MipSalus, TopoTarget A/S (Chairman) and Zymenex A/S, and founder of Scandinavian Medical Research through which he contracted as a medical advisor for Pfizer, Yamanouchi and Synthelabo.
BoD
Martin Rahbek Kornum
- Co-founder of Orphazyme
- Currently: European Patent Specialist at Davis Wright Tremaine LLP, San Francisco
- Previously: Patent Attorney at Høiberg A/S, M.Sc. Human Biology
Observer
Henrijette Richter, Ph.D.
- Investment Director Novo Seeds. Serves on the board of directors of Orphazyme ApS, CytoGuide ApS and MycoTeQ A/S (as chairman)
- Director of Scientific Analysis with Sunstone Capital, and Investment Analyst in Vaekstfondens Life Science Ventures group
- Postdoctoral fellow at Massachusetts Institute of Technology (MIT), Center for Cancer Research. Ph.D. and Industrial Scientist degree in Molecular Biology from the University of Copenhagen